| 25.6 -0.41 (-1.58%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 31.47 | 1-year : | 32.92 |
| Resists | First : | 26.95 | Second : | 28.19 |
| Pivot price | 26.24 |
|||
| Supports | First : | 24.94 | Second : | 20.75 |
| MAs | MA(5) : | 25.82 |
MA(20) : | 26.35  |
| MA(100) : | 27.23 |
MA(250) : | 31.85 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 28.1 |
D(3) : | 30.7 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 47.65 | Low : | 22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MLYS ] has closed above bottom band by 25.3%. Bollinger Bands are 55.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.26 - 26.45 | 26.45 - 26.59 |
| Low: | 25.19 - 25.38 | 25.38 - 25.53 |
| Close: | 25.75 - 26.06 | 26.06 - 26.29 |
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Wed, 26 Aug 2026
Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda - Stock Titan
Wed, 26 Aug 2026
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Tue, 25 Aug 2026
Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan - Stock Titan
Fri, 21 Aug 2026
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - Stock Titan
Thu, 13 Aug 2026
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tue, 11 Aug 2026
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 117.6 (%) |
| Shares Short | 9,310 (K) |
| Shares Short P.Month | 11,100 (K) |
| EPS | -4.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.2 % |
| Return on Equity (ttm) | -80.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -139 (M) |
| Levered Free Cash Flow | -203 (M) |
| PE Ratio | -6.1 |
| PEG Ratio | 0 |
| Price to Book value | 4.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|